A bipartisan push in Washington is demanding answers from the Department of Defense regarding the military’s heavy reliance on foreign-made drugs, specifically those sourced from China and India. Florida Senator Rick Scott, serving as Chairman of the Senate Special Committee on Aging, alongside Ranking Member Kirsten Gillibrand, sent an official inquiry this week to Secretary of War Pete Hegseth.
The letter highlights a growing anxiety among lawmakers that the medications keeping American service members and veterans healthy are increasingly vulnerable to international trade disputes and substandard overseas manufacturing.
The core of the issue lies in the sheer volume of generic drugs used by the U.S. military. Currently, about 91% of all prescriptions in the United States are filled with generics. However, the raw materials and active ingredients needed to make these pills are largely produced abroad.
The senators pointed out that the U.S. has limited oversight over these foreign facilities. They expressed specific concern that if a geopolitical crisis were to occur, countries like China could use their control over the drug supply as leverage, potentially cutting off access to life-saving antibiotics or chronic disease treatments.
This legislative inquiry follows a series of investigative reports and committee hearings held over the last several months. Lawmakers have been examining how the Food and Drug Administration sometimes allows “exemptions” for drugs made in overseas factories that have failed safety inspections, simply to avoid domestic shortages. The committee is now asking the Pentagon to clarify if it is currently stocking any of these “exempt” medications and what the backup plan is if a major supplier suddenly halts exports.
Beyond safety, the senators are pushing for more transparency through the “CLEAR LABELS Act.” This proposed legislation would require medications to clearly state their country of origin, much like the labeling already required for clothing or electronics.
The letter asks Secretary Hegseth to explain how the Department of Defense can prioritize buying American-made drugs to boost national security.
The senators have requested a full briefing on the military’s drug inventory and supply chain mapping by February 28, 2026, emphasizing that the health of the armed forces should not be dependent on the manufacturing whims of foreign adversaries.
READ: U.S. Forces Within Striking Distance: Pentagon Prepared For Weekend Action Against Iran
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
